SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EQUITY FLASH L impact

Johnson & Johnson Reports TREMFYA PsA Study Findings

The company said TREMFYA demonstrated MRI-confirmed improvements in spinal pain and stiffness. The available report also says the treatment showed statistically significant improvement on the BASDAI disease activity score versus an unspecified comparator.

JNJ

Related stories